Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: insert (284), adjoin (2), append (3), affix (14), attach (276), include (1000)

Gemcitabine (21day) ver1.1

Description: Chemotherapy Protocol BLADDER GEMCITABINE (21 day) Regimen Bladder-Gemcitabine Indication Locally advanced or metastatic urothelial cancer in patients unsuitable for cisplatin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-21day-ver1.1.pdf

NIHR expression of interest

Description: NIHR CRN Site Identification Support Expression of Interest (EOI) Guidance (v2 May 2018) The expression of interest process is intended to facili
Url: /Media/Southampton-Clinical-Research/NIHR-expression-of-interest.pdf

Southampton experts to trial 'instant' test for eye infections

Description: Clinicians and engineers in Southampton have developed a microchip that could detect sight-threatening eye infections within minutes – and prevent misuse
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/September-2017/Southampton-experts-to-trial-instant-test-for-eye-infections.aspx

Procedure for circumference measurements of children

Description: NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url: /Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-circumference-measurements-of-children.pdf

Annual-report-24-25-final

Description: 2024/25 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2024/25 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-24-25-final.pdf

Papers CoG 29.04.2025 v2

Description: Date Time Location Chair Agenda Council of Governors 29/04/2025 14:00 - 15:45 Conference Room, Heartbeat/Microsoft Teams Jenni
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-29.04.2025-v2.pdf

Bevacizumab (7.5mgkg), Carboplatin(AUC5) and Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (7.5)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • O
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab7.5mgkgCarboplatinandPaclitaxel21day.pdf

Finance and Performance Reports 2023-24 Month 2 May 2023

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: D
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-2-May-2023.pdf

Carboplatin (AUC5)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5) Regimen • Ovary – Carboplatin (AUC 5) Indication • Adjuvant treatment in patients with moderate to high risk
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5.pdf

Irinotecan Ver 1.2

Description: Chemotherapy Protocol COLORECTAL CANCER Regimen IRINOTECAN Colorectal Cancer– Irinotecan Indication Second line treatment of advanced colorectal cancer WHO performance status 0
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/IrinotecanVer12.pdf

71 to 80 of 682

Previous … 6 7 8 9 10 … Next